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Thromboembolism is a serious complication of induction therapy forchildhood acute lymphoblastic leukemia. We prospectively com-pared the efficacy and safety of antithrombotic interventions in the
consecutive leukemia trials ALL-BFM 2000 and AIEOP-BFM ALL 2009.
Patients with newly diagnosed acute lymphoblastic leukemia (n=949, age 1
to 18 years) were randomized to receive low-dose unfractionated heparin,
prophylactic low molecular weight heparin (enoxaparin) or activity-adapt-
ed antithrombin throughout induction therapy. The primary objective of
the study was to determine whether enoxaparin or antithrombin reduces
the incidence of thromboembolism as compared to unfractionated heparin.
The principal safety outcome was hemorrhage; leukemia outcome was a
secondary endpoint. Thromboembolism occurred in 42 patients (4.4%).
Patients assigned to unfractionated heparin had a higher risk of throm-
boembolism (8.0%) compared with those randomized to enoxaparin
(3.5%; P=0.011) or antithrombin (1.9%; P<0.001). The proportion of
patients who refused antithrombotic treatment as allocated was 3% in the
unfractionated heparin or antithrombin arms, and 33% in the enoxaparin
arm. Major hemorrhage occurred in eight patients (no differences between
the groups). The 5-year event-free survival was 80.9±2.2% among patients
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Introduction
Thromboembolism is a serious complication of gluco-
corticoid and E. coli asparaginase-containing induction
therapy for childhood acute lymphoblastic leukemia
(ALL). Reported incidences vary between 1% and 37%,
depending on the study design and definition of throm-
bosis, as well as diagnostic, supportive and therapeutic
methods.1-6 Acquired antithrombin deficiency as a result
of asparaginase-induced asparagine depletion is consid-
ered to be a crucial mechanism for the development of
thromboembolism during ALL induction therapy. The
presence of a central venous catheter (CVC) seems to be
an additional – at least local – risk factor for thromboem-
bolism as a significant proportion of thromboembolic
events during ALL treatment is related to an indwelling
CVC. Furthermore, the risk of thromboembolism has
been shown to be associated with CVC location and
insertion technique.1,5,7-12 Published data also provide good
evidence that adolescent age is an important risk factor
for thromboembolism whereas the additional impact of
inherited thrombophilia in the context of childhood ALL
treatment is controversial.5,13-16
Sufficiently powered randomized trials on thrombo-
prophylaxis in children during ALL induction therapy
have not been available,16-23 and evidence for the benefit
of specific thromboprophylactic measures has therefore
been lacking so far. In the absence of valid medical stan-
dards of care regarding thromboprophylaxis and the use
of a CVC during ALL induction, various different
approaches existed in the pediatric cancer centers in
Switzerland and Germany in the early 2000s, each based
on individual experiences and institutional standards.
This unsatisfactory situation gave the impetus to initiate
the THROMBOTECT trial, a prospective randomized
study to evaluate the efficacy and safety of antithrombot-
ic prophylaxis in children treated for ALL.
As drug administration through an indwelling CVC
provides significant gain in comfort for the patients and
increases the safety of therapy with tissue-toxic agents,
the THROMBOTECT study was initially designed to
include patients with implanted CVC from the initiation
of the induction phase and was only later on also opened
for patients without CVC. Two mechanisms of action to
prevent thromboembolism were utilized in the two inter-
ventional arms of the trial: inhibition of thrombin
through inactivation of coagulation factor X by treatment
with the low molecular weight heparin enoxaparin
(ClexaneTM) and replacement of antithrombin by the plas-
ma-derived antithrombin preparation KyberninTM to com-
pensate for asparaginase-related aquired antithrombin
deficiency. Being aware of the published data of Nowak-
Göttl et al., which reported an almost 50% incidence of
thromboembolism among ALL patients with a prothrom-
botic defect, and considering the additional risk factor of
an indwelling CVC, a control arm without any interven-
tion appeared difficult to justify.15 The third arm therefore
included continuous infusion of low-dose unfractionated
heparin (UFH) while the CVC was in use, with the aim of
preventing local clot formation at the tip of the catheter,
thereby preventing thrombotic occlusion of the
indwelling CVC without causing relevant systemic anti-
coagulatory effects.7,24-27 Low-dose UFH was, therefore,
considered the control arm.
The current report presents the clinical results of the
THROMBOTECT study with respect to the incidence of
symptomatic thromboembolism and hemorrhage as pri-
mary efficacy and safety outcomes as well as the second-
ary safety outcome of leukemia-related survival.
Methods
Study design 
THROMBOTECT was an open-label, prospective, random-
ized, multicenter study to evaluate two different preventive
antithrombotic measures during induction chemotherapy in
children with ALL treated according to ALL-BFM 2000 (NCT
00430118) and AIEOP-BFM-ALL 2009 treatment protocols (NCT
01117441). THROMBOTECT was an add-on study to the ALL-
BFM protocols and was approved by the leading ethics commit-
tees of the Medical School Hannover, Germany, and St. Gallen,
Switzerland, and by the local ethics committees of each partici-
pating site. Written informed consent to participation in the
study was obtained from guardians and/or patients before ran-
domization. The detailed study protocol is available in the
Online Supplementary Material.
Patients’ eligibility
Patients were eligible if treated on the ALL-BFM 2000 or
AIEOP-BFM ALL 2009 protocol,28-30 if they had a CVC inserted
by day 8 of induction and if the CVC remained in place until at
least day 33. The choice of the CVC and decisions regarding its
maintenance were made by the treating physicians according to
institutional guidelines. In August 2004, the protocol was
amended to allow participation of patients without a CVC.
Exclusion criteria were known hemorrhagic disorders unrelated
to leukemia, active gastrointestinal ulcer, previous cerebrovascu-
lar accident and/or known hypersensitivity to heparin. 
Randomization and study treatment 
After written informed consent had been given, randomiza-
tion was performed by day 8 in a 1:1:1 ratio using permuted
blocks of six patients and stratification by country and the glu-
cocorticoid preparation (dexamethasone or prednisone) admin-
istered during induction.29 Randomization was performed cen-
assigned to antithrombin compared to 85.9±2.0% in the unfractionated heparin group (P=0.06), and
86.2±2.0% in the enoxaparin group (P=0.10). In conclusion, prophylactic use of antithrombin or enoxaparin
significantly reduced thromboembolism. Despite the considerable number of patients rejecting the assigned
treatment with subcutaneous injections, the result remains unambiguous. Thromboprophylaxis - for the
present time primarily with enoxaparin - can be recommended for children and adolescents with acute lym-
phoblastic leukemia during induction therapy. Whether and how antithrombin may affect leukemia out-
come remains to be determined. 
trally by the ALL-BFM study coordination center using comput-
er-generated random number lists. This ensured that the partic-
ipating centers had no access to the allocation sequence. The
assigned arm was submitted to the center by fax.
Patients were randomly assigned to receive one of the two
experimental thromboprophylactic treatments with either the
low molecular weight heparin enoxaparin or with activity-
adjusted antithrombin or to the control arm, i.e., low-dose UFH. 
Thromboprophylaxis was started on day 8 and ended on day
33 of induction chemotherapy (Online Supplementary Figure S1).
The observation period covered the induction and consolidation
phases (Online Supplementary Figure S2) up to and including pro-
tocol day 64. 
Patients in the enoxaparin group received ClexaneTM at a dose
of 80-100 IU/kg body weight once daily subcutaneously31-34 with
a target anti-Xa level not exceeding 0.4 U/L, measured 4 h after
the third or fourth injection. On days with lumbar puncture or
other invasive procedures, enoxaparin was postponed until at
least 4 h after the procedure. In the case of thrombocytopenia
<30 x 109/L, platelet tranfusion was required or enoxaparin had
to be withheld until platelet regeneration. 
In the antithrombin group, antithrombin activity was meas-
ured every 3 days prior to each asparaginase administration. If
antithrombin activity was below the lower limit of normal of
80%, the plasma-derived antithrombin preparation KyberninTM
was substituted calculating the dose according to the formula
[antithrombintarget 100% – antithrombinactual] x kg body weight
targeting at 100% AT activity. 
Patients assigned to the control arm received UFH at a dose of
2 IU/kg body weight/h as long as an infusion drip was running
to prevent local thrombotic occlusion of the indwelling CVC.24
Treatment with coagulation factors or anticoagulants beyond
the interventions intended per protocol was not allowed unless
clinically indicated. Management of thromboembolism was at
the discretion of the treating physician.
Outcome measures
The diagnosis of thromboembolism was based on clinical sus-
picion and had to be confirmed by one or more suitable imaging
methods within a routine diagnostic work-up (Online
Supplementary Table S1). No systematic provision was made for
blinding the attending physicians or radiologists to the random-
ization arm. Intermittent dysfunction of the CVC by a clot at the
tip of the catheter was not considered a thrombotic event as
long as CVC patency was restored. The principal safety out-
come was absence of bleeding complications during the study
period. The definition of major and minor hemorrhage met
internationally defined standards (Online Supplementary Table
S2).35-37 Secondary safety outcomes were event-free survival and
overall survival. Event-free survival was defined as the time
from diagnosis to the date of last follow-up or first event. Events
were resistance to therapy, leukemia relapse, secondary neo-
plasm or death from any cause. Failure to achieve remission due
to early death or resistance was considered as an event at time
zero. Survival was defined as time from diagnosis to the date of
last follow-up or death from any cause. 
Statistical analysis
The primary objective was to test whether antithrombotic
prophylaxis with enoxaparin or antithrombin was superior to
that with UFH. The null hypothesis was that there was no dif-
ference between enoxaparin or antithrombin versus UFH tested
with a one-tailed Fisher exact test at a significance level of
P=0.025 each. The main analysis was by intention-to-treat. In
order to reach a power of 85% with a significance level of 0.025,
315 patients had to be randomized per group, assuming an event
rate of 9% within the UFH group and 3% in the two interven-
tional groups. If both comparisons were significantly different,
the thrombosis rates in the enoxaparin and antithrombin arm
had to be tested for equivalence (secondary objective).
Antithrombin replacement and enoxaparin therapy would be
considered equivalent if the two-sided 95% confidence interval
(95% CI) of the incidence difference did not exceed ±4%. For
the equivalence test, patients were analyzed according to the
treatment given (as treated). 
The Kaplan-Meier method38 was used to estimate survival
rates, and differences were compared with the log-rank test.39 A
Cox proportional hazards model was used in univariate and
multivariate survival analyses.40 Cumulative incidence functions
for competing events were constructed by the method of
Kalbfleisch and Prentice41 and compared with the Gray test.42
Odds ratios were calculated to compare the risks of thromboem-
bolic events. Except for the confirmatory analyses of the pri-
mary study question, all other analyses were exploratory.
Results
Patients’ characteristics
From December 1, 2002, to December 31, 2011, 1526
patients with ALL treated at one of the 26 study centers
in Germany and Switzerland were eligible for randomiza-
tion (Figure 1). Of these, 577 patients were not random-
ized, the vast majority because patients and/or parents
refused consent to be randomized to the enoxaparin arm
as they did not wish to accept a daily subcutaneous injec-
tion. Nine hundred and forty-nine patients (the popula-
tion for the intention-to-treat analyses) were randomly
assigned to receive either UFH (n=312), enoxaparin
(n=317) or antithrombin (n=320). Randomized and non-
randomized eligible patients did not differ with respect to
their initial characteristics (Online Supplementary Table S3).
The proportions of patients with a poor response to the
prednisone prephase (prednisone poor-responders) and a
slow treatment response as assessed by minimal residual
disease were significantly higher in the group of non-ran-
domized patients. In the intention-to-treat population,
numbers and characteristics of patients were well-bal-
anced between the three randomization arms except for
a slight imbalance in the age distribution with fewer chil-
dren below 6 years in the enoxaparin group (Table 1).
Patients’ characteristics were evenly distributed between
the randomization arms as treated except for a signifi-
cantly lower proportion of patients below 6 years of age
in the enoxaparin arm (details provided in Online
Supplementary Table S4).
The proportion of patients who refused antithrombotic
treatment as allocated was 3% in patients randomized to
UFH (10/312) or antithrombin (11/320), and 33%
(105/317) in those assigned to enoxaparin (Figure 1).
Rejection of the enoxaparin arm was more frequent in
patients below 6 years of age than in older patients
[62/157 (39%) versus 42/160 (27%), respectively] with a
preferential switch to UFH in the younger cohort (Online
Supplementary Table S5). Based on this finding additional
exploratory analyses with respect to thromboembolism
rate and leukemia-related outcomes were performed,
stratified by age and in the as-treated groups.
J. Greiner et al.
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Figure 1. Consolidated standards for reporting of trials (CONSORT) diagram. AT: antithrombin; E: enoxaparin; UFH: unfractionated heparin.
Table 1. Patients’ characteristics by thromboprophylaxis group as assigned by randomization.
                                                                      Total (n=949)                              UFH (n=312)                   Enoxaparin (n=317)            Antithrombin (n=320)
                                                                             N (%)                                          N (%)                                    N (%)                                    N (%)
Study                                                                                                                                                                                                                                                                  
ALL-BFM 2000                                                            815 (85.9)                                           269 (86.2)                                   272 (85.8)                                    274 (85.6)
AIEOP-BFM ALL 2009                                               134 (14.1)                                            43 (13.8)                                     45 (14.2)                                      44 (13.8)
Sex                                                                                                                                                                                                                                                                     
Male                                                                             537 (56.6)                                           173 (55.4)                                   183 (57.7)                                    181 (56.6)
Female                                                                         412 (43.4)                                           139 (44.6)                                   133 (42.3)                                    139 (43.4)
Age                                                                                                                                                                                                                                                                     
1≤6 years                                                                    512 (54.0)                                           174 (55.8)                                   157 (49.5)                                    181 (56.6)
6≤10 years                                                                  188 (19.8)                                            57 (18.3)                                     72 (22.9)                                      59 (18.4)
≥ 10 years                                                                   249 (26.2)                                            81 (26.0)                                     88 (27.8)                                      80 (25.0)
Central venous catheter                                                                                                                                                                                                                               
CVC in site                                                                  896 (94.4)                                           295 (94.6)                                   294 (93.3)                                    303 (95.2)
No CVC                                                                          53 (5.6)                                                17 (5.4)                                       21 (6.7)                                        15 (4.8)
WBC at diagnosis (x109/L)                                                                                                                                                                                                                            
< 20                                                                              599 (63.1)                                           199 (63.8)                                   212 (66.9)                                    188 (58.8)
20 ≤ 100                                                                       249 (26.2)                                            83 (26.6)                                     76 (24.0)                                      90 (28.1)
100 ≤200                                                                        53 (5.6)                                                15 (4.8)                                       14 (4.4)                                        24 (7.4)
≥ 200                                                                              47 (5.0)                                                15 (4.8)                                       14 (4.4)                                        18 (5.6)
CNS status                                                                                                                                                                                                                                                        
CNS negative                                                             872 (91.9)                                           278 (89.1)                                   298 (94.0)                                    296 (92.5)
CNS positive                                                                30 (3.2)                                                14 (4.4)                                        6 (1.9)                                         10 (3.1)
No information                                                            47 (5.0)                                                20 (6.4)                                       13 (4.1)                                        14 (4.4)
Immunophenotype                                                                                                                                                                                                                                         
Non-T-ALL                                                                   827 (87.1)                                           264 (84.6)                                   298 (89.0)                                    281 (87.8)
T-ALL                                                                            120 (12.6)                                            47 (15.1)                                     34 (10.7)                                      39 (12.3)
No information                                                             2 (0.2)                                                  1 (0.3)                                         1 (0.3)                                          0 (0.0)
continued on the next page
Thromboembolic events
Among the 949 randomized patients, 42 thromboem-
bolic events were observed (4.4%; 95% CI: 3.2 to 5.9). Of
these events, 20 (47.6%) occurred in the upper deep
venous system, seven (16.7) in the lower deep venous
system, and 13 (30.9%) in cerebral sinus veins; two
patients (4.8%) had a cerebral arterial stroke. Eight of the
42 thromboembolic events (19%) were distant to the site
of the CVC. Thirty-three events occurred between treat-
ment day 9 and 36 during induction therapy, the other
nine events occurred between treatment day 37 and 52 of
induction consolidation. 
Children below 6 years of age had a significantly lower
risk of thromboembolism (14/512, 2.7%) than those aged
6 to 9 years (11/188, 5.9%) or 10 years and older (17/249,
6.8%; P=0.018). Other patients’ characteristics and fea-
tures, such as gender, initial white blood cell count,
immunophenotype or treatment response did not influ-
ence the incidence of thromboembolism (data not shown).
The incidence of thromboembolism was significantly
higher among patients randomized to UFH (25/312;
8.0%) than in the enoxaparin (11/317; 3.5%; P=0.011) or
antithrombin group (6/320; 1.9%; P<0.001). The as-treat-
ed analysis revealed an incidence of 6.7% in the UFH
group (25/372) compared to 3.2% in the enoxaparin
(7/216; P=0.089) and 2.6% in the antithrombin group
(9/341; P=0.013). The respective cumulative incidences
are depicted in Figure 2A,B. The difference between the
incidence of thromboembolism in the enoxaparin and
antithrombin groups as treated was -0.6%; the lower and
upper limits of the 95% CI were -3.5% and +2.3%,
respectively (P-values for the corresponding one-sided
tests were P=0.01 and P=0.001). Thus, antithrombin and
enoxaparin were equally effective.
J. Greiner et al.
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                                                                      Total (n=949)                              UFH (n=312)                   Enoxaparin (n=317)            Antithrombin (n=320)
                                                                             N (%)                                          N (%)                                    N (%)                                    N (%)
Genetics                                                                                                                                                                                                                                                           
t(12;21) / TEL-AML1                                                                                                                                                                                                                                      
Negative                                                                      722 (76.1)                                           235 (75.3)                                   245 (77.3)                                    242 (75.6)
Positive                                                                        199 (21.0)                                            65 (20.8)                                     63 (19.9)                                      71 (22.2)
No information                                                            28 (3.0)                                                12 (3.8)                                        9 (2.8)                                         7 (2.2)
t(9;22) / BCR-ABL                                                                                                                                                                                                                                            
Negative                                                                      924 (97.4)                                           303 (97.1)                                   309 (97.5)                                    312 (97.5)
Positive                                                                          25 (2.6)                                                 9 (2.9)                                         8 (2.5)                                          8 (2.5)
No information                                                             0 (0.0)                                                  0 (0.0)                                         0 (0.0)                                          0 (0.0)
t(4;11) / MLL-AF4                                                                                                                                                                                                                                            
Negative                                                                      942 (99.3)                                           311 (99.7)                                   314 (99.1)                                    317 (99.1)
Positive                                                                           7 (0.7)                                                  1 (0.3)                                         3 (0.9)                                          3 (0.9)
No information                                                             0 (0.0)                                                  0 (0.0)                                         0 (0.0)                                          0 (0.0)
Peripheral blast count 
on day 8 (prednisone 
response)                                                                                                                                                                                                                                                        
< 1x109/L (PGR)                                                        880 (92.7)                                           291 (93.3)                                   295 (93.1)                                    294 (91.9)
≥ 1x109/L (PPR)                                                           65 (6.8)                                                19 (6.1)                                       22 (6.9)                                        24 (7.5)
No information                                                             4 (0.4)                                                  2 (0.6)                                         0 (0.0)                                          2 (0.6)
Risk group                                                                                                                                                                                                                                                        
Standard                                                                      301 (31.7)                                            97 (31.1)                                    101 (32.1)                                    101 (31.8)
Medium                                                                       512 (54.0)                                           171 (54.8)                                   169 (53.7)                                    170 (53.5)
High                                                                              136 (14.3)                                            44 (14.1)                                     45 (14.3)                                      47 (14.8)
MRD at end of induction                                                                                                                                                                                                                              
Negative                                                                      303 (31.9)                                           103 (33.0)                                   104 (32.8)                                     96 (30.0)
< 5 x 10-4                                                                      316 (33.3)                                           107 (34.2)                                   113 (35.6)                                     96 (30.0)
≥ 5 x 10-3                                                                       184 (19.4)                                            57 (18.3)                                     58 (18.3)                                      69 (21.6)
No information                                                          146 (15.4)                                            45 (14.4)                                     42 (13.2)                                      59 (18.4)
MRD at week 12                                                                                                                                                                                                                                              
Negative                                                                      579 (61.0)                                           187 (59.9)                                   202 (63.7)                                    190 (59.4)
< 5 x 10-4                                                                      146 (15.4)                                            53 (17.0)                                     47 (14.8)                                      46 (14.4)
≥ 5 x 10-3                                                                         43 (4.5)                                                16 (5.1)                                       12 (3.8)                                        15 (4.7)
No information                                                          181 (19.1)                                            56 (17.9)                                     56 (17.7)                                      69 (21.6)
Randomized in induction
in AIEOP-BFM ALL 2000*                                                                                                                                                                                                                             
Randomized                                                                                                                                                                                                                                                   
assigned to prednisone                                        125 (13.2)                                            39 (12.5)                                     41 (12.9)                                      45 (14.1)
assigned to dexamethasone                                136 (14.3)                                            45 (14.4)                                     45 (14.2)                                      46 (14.4)
Not randomized                                                         688 (72.5)                                           228 (73.1)                                   231 (72.9)                                    229 (71.6)
*For details see Figure S2 in the Online Supplementary Appendix and Möricke et al., Blood (2016).19 CNS: central nervous system; CVC: central venous catheter; MRD: minimal
residual disease; PGR: prednisone good-response; PPR: prednisone poor-response; UFH: unfractionated heparin; WBC: white blood cell count.
continued from the previous page
Exploratory as-treated analyses stratified by age (Figure
2D,F) demonstrated a significantly reduced risk of throm-
boembolism in patients 6 years of age or older when
treated in one of the experimental arms compared to the
risk in the control group [UFH: 18/158, 11.4%; enoxa-
parin: 5/120, 4.2%, P(versus UFH)=0.001; antithrombin
4/150, 2.7%, P(versus UFH)<0.001]. No significant differ-
ences were found among patients below 6 years of age
(UFH 7/214, 3.3%; enoxaparin 2/96, 2.1%; antithrombin
5/191, 2.6%).
No formal test for interaction was done for the sub-
group analysis by age. Applying Fine-Gray models with
interaction terms for age older than 6 years and enoxa-
parin/antithrombin, the interactions were not significant.
This, however, does not entirely exclude interactions
since the power of such tests is low.
Hemorrhage
Eight bleeding episodes were documented among the
949 randomized patients (0.9%). Four of them occurred
during induction chemotherapy under antithrombotic
prophylaxis and four during consolidation after termina-
tion of the anticoagulants. All hemorrhages were classi-
fied as major (7 gastrointestinal, 1 cerebral). Four patients
with hemorrhage were treated in the UFH group (1.1%),
three in the antithrombin group [0.9%, P(versus
UFH)=1.0] and one patient in the enoxaparin group
[0.5%, P(versus UFH)=0.66].
Leukemia outcome and survival 
The 5-year probability of event-free survival and cumu-
lative incidence of relapse of the THROMBOTECT
cohort were comparable to those of the 577 non-random-
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Figure 2. Thromboembolic events according to the randomization arms. Results are shown by intention to treat (A, C and E) and by treatment as given (B, D and
F) for the total cohort (A and B) and stratified by age <6 years (C and D) and ≥6 years (E and F). Events are depicted as cumulative incidence curves. The P values
indicated were calculated with the Fisher exact test. CI: confidence interval; OR: odds ratio; TE: thromboembolism; UFH: unfractionated heparin.  
A B
C D
E F
ized patients (THROMBOTECT cohort: 5-year probabil-
ity of event-free survival 84.3±1.2%, 5-year cumulative
incidence of relapse 11.7±1.1%; non-randomized
patients: 5-year probability of event-free survival
84.0±1.6%, 5-year cumulative incidence of relapse
11.8±1.4). Patients randomized to the antithrombin arm
had a 5-year probability of event-free survival of
80.9±2.2% compared with those assigned to enoxaparin
(86.2±2.0%, P=0.10) or UFH (85.9±2.0%, P=0.06) (Figure
3A) with a hazard ratio of 1.40 (1.02-1.92; P=0.040) for
the antithrombin arm versus the remaining patients. The
probability of overall survival at 5 years was similar in all
three arms (antithrombin 89.8±1.7%, enoxaparin
90.9±1.6%, UFH 92.4±1.5%). The differences observed
in the event-free survival were due to a higher incidence
of late relapses in the antithrombin group that in the
other groups (Figure 3C); the as-treated analyses showed
no statistically significant differences between the three
groups [hazard ratio for the antithombin group versus the
other groups: 1.16 (0.84-1.59); P=0.37) (Figure 3B,D).
Retrospective exploratory subgroup analyses revealed a
higher incidence of relapse among the antithrombin-
treated patients, but only within the medium-risk group
(Online Supplementary Figure S3). Multivariate Cox regres-
sion analyses on event-free survival were performed
including risk group according to respective trial criteria,
TEL-AML1 status, initial white blood cell count, age and
the THROMBOTECT arm as covariates. Hazard ratios
for the antithrombin arm were 1.38 (0.99-1.91; P=0.054)
for the intention-to-treat analysis and 1.19 (0.86-1.66;
P=0.269) for the as-treated analysis and thus comparable
with those of the univariate analyses (Online
Supplementary Table S6).
To test for a potential dose effect of antithrombin,
doses given were analyzed in patients treated in the
antithrombin arm. Data available for 248 of 341 patients
(72.7%) did not disclose a dose-related effect on the
relapse incidence (Online Supplementary Figure S4).
Discussion
Reliable data on thromboembolism during induction
therapy of childhood ALL are scarce. The only random-
ized interventional trial was the PARKAA trial
(Prophylactic antithrombin replacement in kids with ALL
treated with L-asparaginase), designed to determine
whether there was a trend to efficacy and safety of
antithrombin treatment but not powered to prove it.16 To
our knowledge, no other data from adequately designed
and powered studies have been available so far to provide
sufficient evidence that would allow valid recommenda-
tions.4,5,9,19,20,23,43,44
The THROMBOTECT trial shows, for the first time,
that prophylactic antithrombotic interventions signifi-
cantly reduce thromboembolism during ALL induction
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Figure 3. Outcome of acute lymphoblastic leukemia according to the THROMBOTECT randomization arms. (A,B) Event-free survival and (C,D) cumulative incidence
of relapse are shown by intention to treat (A,C) and by treatment as given (B,D). Numbers of patients at risk in the event-free survival graphs also apply to the respec-
tive relapse incidence graphs. 5 y-pEFS: 5-year probability of event-free survival; 5 y-CIR: 5-year cumulative incidence of relapse; SE: standard error; UFH: unfrac-
tionated heparin. 
A B
C D
therapy as compared to a control. Both interventions,
enoxaparin and activity-adapted Antithrombin substitu-
tion, were equally effective. Asparaginase-induced
antithrombin deficiency is assumed to be the most impor-
tant mechanism for the development of thromboem-
bolism during ALL induction therapy.45 As a consequence
of asparagine depletion, asparaginase therapy leads to
intracellular retention of a misfolded antithrombin, result-
ing in acquired antithrombin deficiency.45,46 The THROM-
BOTECT trial demonstrated that maintaining antithrom-
bin activity at 80% or higher throughout the induction
phase could significantly protect patients from throm-
boembolism. Thus, correction of low antithrombin activ-
ity seems to be one effective way to prevent thromboem-
bolism, this being consistent with clinical and laboratory
data on antithrombin supplementation.10,16,18,19,47
A considerable number of patients eligible for the study
were not randomized. In this group the rate of pred-
nisone poor-responders was significantly higher than in
the THROMBOTECT cohort. This may be attributed to
a tendency of the doctors or parents to avoid additional
burden from interventions of an add-on trial in particular
in those patients with very poor response during the first
days of treatment. However, patients’ characteristics
were comparable between the three randomization
groups except for a slight underrepresentation of younger
patients assigned to enoxaparin. The main reason for not
participating was refusal to accept the daily subcutaneous
enoxaparin injections. Not surprisingly, the proportion of
patients and parents refusing the assigned enoxaparin
was highest in young children. This demonstrates not
only their reluctance to receive injections but also under-
lines a considerable drawback in practical use, irrespec-
tive of the antithrombotic efficacy of enoxaparin. 
Older age proved to be an important risk factor for
thromboembolism, as has been reported earlier by oth-
ers.1,13,48 The best cut-off in our data was the age of 6
years. Exploratory analyses suggested that the benefit
from either experimental arm was more pronounced in
older patients than in young children. The significant
benefit in risk reduction of thromboembolism with
either intervention, enoxaparin or antithrombin, as com-
pared to UFH, provides a convincing rationale for throm-
boprophylaxis in this age group. For younger children,
the incidence of thromboembolism was low and compa-
rable in all three randomization arms. The need for
thromboprophylaxis in ALL patients below 6 years of
age could, therefore, be questioned. However, the study
was not powered for subgroup analyses and the lack of
statistical difference in the incidences of thromboem-
bolism between the treatment groups in younger chil-
dren may be due to insufficient power caused by the
number of patients as well as the lower incidence of
thromboembolism. Furthermore, in younger children
thromboembolism may be missed as symptoms are
often subtle. This is in line with the findings of the
PARKAA study, which showed that children with symp-
tomatic thromboembolism tend to be older than those
with clinically asymptomatic thromboembolism.16 Even
if clinically not diagnosed, asymptomatic thromboem-
bolism may be associated with significant vessel occlu-
sion.16 This, in turn, can lead to destruction of the vessel
wall, causing long-term morbidity in terms of post-
thrombotic syndrome, likely becoming apparent years
after the end of ALL therapy. Whether this applies to
young patients with ALL remains unknown.17 Future
studies with sufficient statistical power are needed to
ascertain whether such interventions in small children
are justified. Nevertheless, although the high proportion
of patients who refused allocation to the enoxaparin arm
may complicate the interpretation of the results in this
treatment arm, the reduction of thromboembolism in the
global analysis appears to be sufficiently convincing to
recommend thromboprophylaxis not only for older
patients but for all age groups, all the more as hemor-
rhage is of no concern.
Most thrombotic events occurred between induction
treatment day 9 and 36, the latter marking the start of
induction consolidation. This confirms our experience
that thromboembolism only rarely occurs at the time of
ALL diagnosis but rather in the course of induction ther-
apy. Furthermore, not all centers were able to get a CVC
inserted at the time of ALL diagnosis. For these reasons,
thromboprophylaxis was started after the prednisone
prephase on day 8 of induction therapy. The primary
objective of the THROMBOTECT trial was to evaluate
efficacy and safety of different prophylactic antithrom-
botic interventions during ALL induction therapy. The
duration of thromboprophylaxis was, therefore, limited
to induction therapy until day 33. Some of the throm-
boembolic events occurred after the end of the induction
phase. However, only a few of these patients had already
started the consolidation phase when the thrombosis was
diagnosed. Factors that may have contributed to these
late thromboses could be concurrent medical issues such
as infections. Given the gradual development of a clot, a
still asymptomatic thrombosis might have started to
develop towards the end of induction therapy and only
become symptomatic in early induction consolidation.
Since pegylated asparaginase is presently used more fre-
quently - in the AIEOP-BFM ALL 2009 trial, the second
dose of this drug was given on day 26 of induction - late
thromboses in induction consolidation might become
more relevant as the use of pegylated asparaginase may
lead to longer asparagine depletion with disturbed coagu-
lation patterns, including extended dysfunction of
antithrombin. Irrespective of possible concomitant pro-
thrombotic risk situations, the hypercoagulable state
seems to remain beyond the end of induction therapy.
Given the very low rate of hemorrhage it might, there-
fore, be advisable to extend thromboprophylaxis accord-
ingly.
The open label assignment as well as the diagnosis of
thromboembolism made on clinical suspicion only are
drawbacks of the THROMBOTECT study design.
However, masking the antithrombotic intervention
would have meant that all patients in all randomization
groups would have had to have been given subcutaneous
injections, including those in the UFH and antithrombin
groups containing placebo. To conduct the study as a
double-blinded trial with double dummy subcutaneous
injections was not considered feasible in a large pediatric
population. 
Similar concerns apply to the primary outcome defined
as thromboembolism based on clinical suspicion. The
PARKAA study showed that a high incidence of clinically
not recognized thromboses can be found by routine imag-
ing screening.16 To overcome observer bias, various and
repeated routine imaging screening for vessel occlusion at
all possible anatomical sites would have been mandatory
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at predefined time points. This comprises ultrasound but
also magnetic resonance imaging which, in young chil-
dren, often requires general anesthesia. In addition, for the
time being the appropriate time points to look for vessel
occlusion are not known and hence the possibility of
missing a thrombosis at arbitrarily chosen time points
would be high. Exposing children to repeated extra anes-
thesia with a questionable benefit was considered too
high an additional burden. The study design chosen was,
therefore, in favor of an open-label treatment. Imaging
was performed on clinical suspicion despite the acknowl-
edged inherent drawbacks. 
Evaluation of event-free survival and relapse rate within
the THROMBOTECT randomization groups revealed the
unexpected finding that patients randomized to the
antithrombin group had a higher incidence of relapse com-
pared to those in the enoxaparin and UFH groups. The dif-
ferences were no longer obvious in the as-treated analysis
and were apparent in the medium-risk group only.
Although a causal relationship between the cumulative
antithrombin dose and the relapse rate could not be estab-
lished, the possibility that antithrombin substitution might
affect leukemia outcome cannot be entirely excluded. 
In conclusion, the THROMBOTECT study has, for the
first time, demonstrated that activity-targeted antithrom-
bin replacement as well as the use of enoxaparin lead to
a significant risk reduction for thromboembolism during
ALL induction therapy when compared with low-dose
UFH. Bleeding was not a major concern.
Thromboprophylaxis during induction therapy can,
therefore, be recommended for children and adolescents
with ALL. The higher incidence of late relapses in chil-
dren with medium-risk ALL assigned to the antithrombin
group remains to be resolved and leads us to recommend,
at present, primarily enoxaparin. Whether thrombopro-
phylaxis contributes to minimize not only clinical but
also silent thromboses and by that long-term morbidity in
terms of post-thrombotic syndrome remains to be deter-
mined. The THROMBOTECT results provide the ration-
ale for new studies, both to elucidate a possible impact of
antithrombin on leukemia outcome and to further deter-
mine the best practice to prevent thromboembolism dur-
ing ALL induction chemotherapy.
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